Clinical characteristics and outcomes of CLL patients
| Patient no. . | Sex . | Matutes score . | Binet stage . | Treatment . | Time (months) between treatment and study . | Age (years) at time of study . | Culture conditions . | Chromosomal aberrations . | Apoptosis in vitro . |
|---|---|---|---|---|---|---|---|---|---|
| CLL-1 | Male | 5 | A | Yes | 19 | 89 | CPG | Karyotype not done//del 13q14, del ATM | Resistant |
| CLL-2 | Male | 4 | C | Yes | 114* | 65 | CPG | Karyotype not done//+12 | Resistant |
| CLL-3 | Male | 5 | B | No | 0 | 53 | CPG | 46,XY,del(11)(q1?4q2?3)[2]/46,XY[18]//del 13q14, del ATM | Resistant |
| CLL-4 | Male | 5 | B | Yes | 72 | 76 | CPG | 46,XY,t(14;18)(q32;q21)[11]/46,idem,del(13) (q14q3?1)[6]/46,XY[2]//del13q14 | Resistant |
| CLL-5 | Male | 4 | B | Yes | 11 | 70 | CPG | 46,XY[10]//del 13q14, del TP53 | Resistant |
| CLL-6 | Male | 5 | C | Yes | 3 | 55 | TPA1 | 46, XY[20]//del 13q14 | Resistant |
| CLL-7 | Female | 5 | A | No | 0 | 60 | CPG | 47,XX,del(11)(q1?3q2?3),del(17)(p12),add(9)q(34), +mar1[cp4]/47,XX,add(2)(p2?4), del(11)(q1?3q2?3),del(17)(p12),+mar2[cp4]/46, XX[5]//del13q14,† del TP53 | Resistant |
| CLL-8 | Female | 5 | A | Yes | 5* | 75 | CPG | 45,XX,der(17)t(17;18)(p12;p11),-18[7]/45,idem, add(2)(q37)[2]//del 13q14, del TP53 | Resistant |
| CLL-9 | Male | 4 | A | Yes | 75 | 65 | CPG | 46, XY[14]//del 13q14, del TP53 | Resistant |
| CLL-10 | Male | 5 | A | No | 0 | 73 | CPG2 | 46,XY,t(12;15)(q24;q21)[7]/46,XY,t(4;15) (q34;q2?1)[2]/46,XY,del(6)(p22), del(13)(q14q33)[2]/46,XY[9]//del13q14 | Resistant |
| CLL-11 | Female | 5 | Yes | 17 | 77 | CPG | 46,XX,t(2;13)(p1?2;q14)[20]//del13q14 | Resistant | |
| CLL-12 | Female | 5 | A | Yes | 54 | 55 | TPA1 | 46,XX,del(13)(q?21q31)[1]/46,XX[19]//del13q14,† delATM‡ | Resistant |
| CLL-13 | Male | 4 | A | No | 0 | 74 | CPG | 46, XY[20]//del 13q14 | Resistant |
| CLL-14 | Male | 4 | B | No | 0 | 78 | CPG | 46,XY,del(11)(q2?2)[6]/46,XY[7]//del 13q14, del ATM | Not done |
| CLL-15 | Female | 5 | yes | 24 | 78 | CPG | 46,XX,del(11)(q14q23)[16]/46,idem,del(6) (q1?4q2?5)[1]/46,XX[3]//del 13q14, del ATM | Not done | |
| CLL-16 | Male | 5 | B | Yes | 1* | 64 | TPA | 46,XY,del(11)(q1?4)[4]//del 13q14, del ATM | Not done |
| CLL-17 | Male | 4 | B | No | 0 | 58 | CPG | 46,XY,del(1)(q3?1),add(3)(p2?6),t(?;7)(?;?) [cp2]/46,XY,del(1)(q3?1),add(2)(p2?4), del(3)(p2?2),add(7)(q3?5)[cp5]/46,XY[13]//del 13q14, del ATM | Not done |
| CLL-18 | Male | 5 | B | No | 0 | 53 | CPG | 46,XY,t(3;20;13)(p2?2;q12;q14),del(11)(q14) [18]/46,XY[2]//del 13q14, del ATM | Not done |
| CLL-19 | Male | 5 | B | No | 0 | 67 | TPA1 | 47,XY,+12[3]/46,XY[12]//+12 | Sensitive |
| CLL-20 | Female | 5 | A | No | 0 | 73 | CPG | 46,XX[20]//del 13q14† | Sensitive |
| CLL-21 | Male | 5 | A | No | 0 | 72 | TPA2 | 46,XY[20]//del 13q14 | Sensitive |
| CLL-22 | Female | 5 | A | No | 0 | 71 | TPA1 | 47,XX,+12[2]/46,XX[8]//+12 | Sensitive |
| CLL-23 | Male | 5 | B | No | 0 | 54 | CPG | 46,XY[18]//del13q14† | Sensitive |
| CLL-24 | Female | 5 | A | No | 0 | 83 | TPA | 46,XX[20]//del ATM | Sensitive |
| CLL-25 | Female | 4 | A | Yes | 48 | 59 | CPG | 46,XX,del(13)(q14q2?1),add(17)(p12)[cp5]/45-46,idem,-8,-17,+2∼3mar[cp10]/46,XX,del(6) (q1?6q2?4),-9,add(18)(q22),+mar[cp5]// del13q14, del TP53 | Sensitive |
| CLL-26 | Male | 4 | A | Yes | 72 | 53 | CPG | 47,XY,+12[14]/47,idem,der(4)?inv(4)(p?13q?22) t(4;17)(?q31;q22)[3]/46,XY[3]//+12,del13q14§ | Sensitive |
| CLL-27 | Male | 4 | A | No | 0 | 55 | TPA1 | 47,X,-Y,+12,+19[6]/46,XY[14]//+12 | Sensitive |
| CLL-28 | Female | 4 | B | No | 0 | 86 | CPG | 46,XY[20]//del 13q14 | Sensitive |
| CLL-29 | Male | 4 | A | No | 0 | 76 | TPA1 | 46,XY[20]//del 13q14, del TP53 | Sensitive |
| ctrl-1 | Male | 0 | 0 | No | 0 | 26 | CPG | Karyotype not done//no abnormalities | Sensitive |
| ctrl-2 | Male | 0 | 0 | No | 0 | 52 | CPG | Karyotype not done//no abnormalities | Sensitive |
| ctrl-3 | Male | 0 | 0 | No | 0 | 54 | CPG | Karyotype not done//no abnormalities | Sensitive |
| Patient no. . | Sex . | Matutes score . | Binet stage . | Treatment . | Time (months) between treatment and study . | Age (years) at time of study . | Culture conditions . | Chromosomal aberrations . | Apoptosis in vitro . |
|---|---|---|---|---|---|---|---|---|---|
| CLL-1 | Male | 5 | A | Yes | 19 | 89 | CPG | Karyotype not done//del 13q14, del ATM | Resistant |
| CLL-2 | Male | 4 | C | Yes | 114* | 65 | CPG | Karyotype not done//+12 | Resistant |
| CLL-3 | Male | 5 | B | No | 0 | 53 | CPG | 46,XY,del(11)(q1?4q2?3)[2]/46,XY[18]//del 13q14, del ATM | Resistant |
| CLL-4 | Male | 5 | B | Yes | 72 | 76 | CPG | 46,XY,t(14;18)(q32;q21)[11]/46,idem,del(13) (q14q3?1)[6]/46,XY[2]//del13q14 | Resistant |
| CLL-5 | Male | 4 | B | Yes | 11 | 70 | CPG | 46,XY[10]//del 13q14, del TP53 | Resistant |
| CLL-6 | Male | 5 | C | Yes | 3 | 55 | TPA1 | 46, XY[20]//del 13q14 | Resistant |
| CLL-7 | Female | 5 | A | No | 0 | 60 | CPG | 47,XX,del(11)(q1?3q2?3),del(17)(p12),add(9)q(34), +mar1[cp4]/47,XX,add(2)(p2?4), del(11)(q1?3q2?3),del(17)(p12),+mar2[cp4]/46, XX[5]//del13q14,† del TP53 | Resistant |
| CLL-8 | Female | 5 | A | Yes | 5* | 75 | CPG | 45,XX,der(17)t(17;18)(p12;p11),-18[7]/45,idem, add(2)(q37)[2]//del 13q14, del TP53 | Resistant |
| CLL-9 | Male | 4 | A | Yes | 75 | 65 | CPG | 46, XY[14]//del 13q14, del TP53 | Resistant |
| CLL-10 | Male | 5 | A | No | 0 | 73 | CPG2 | 46,XY,t(12;15)(q24;q21)[7]/46,XY,t(4;15) (q34;q2?1)[2]/46,XY,del(6)(p22), del(13)(q14q33)[2]/46,XY[9]//del13q14 | Resistant |
| CLL-11 | Female | 5 | Yes | 17 | 77 | CPG | 46,XX,t(2;13)(p1?2;q14)[20]//del13q14 | Resistant | |
| CLL-12 | Female | 5 | A | Yes | 54 | 55 | TPA1 | 46,XX,del(13)(q?21q31)[1]/46,XX[19]//del13q14,† delATM‡ | Resistant |
| CLL-13 | Male | 4 | A | No | 0 | 74 | CPG | 46, XY[20]//del 13q14 | Resistant |
| CLL-14 | Male | 4 | B | No | 0 | 78 | CPG | 46,XY,del(11)(q2?2)[6]/46,XY[7]//del 13q14, del ATM | Not done |
| CLL-15 | Female | 5 | yes | 24 | 78 | CPG | 46,XX,del(11)(q14q23)[16]/46,idem,del(6) (q1?4q2?5)[1]/46,XX[3]//del 13q14, del ATM | Not done | |
| CLL-16 | Male | 5 | B | Yes | 1* | 64 | TPA | 46,XY,del(11)(q1?4)[4]//del 13q14, del ATM | Not done |
| CLL-17 | Male | 4 | B | No | 0 | 58 | CPG | 46,XY,del(1)(q3?1),add(3)(p2?6),t(?;7)(?;?) [cp2]/46,XY,del(1)(q3?1),add(2)(p2?4), del(3)(p2?2),add(7)(q3?5)[cp5]/46,XY[13]//del 13q14, del ATM | Not done |
| CLL-18 | Male | 5 | B | No | 0 | 53 | CPG | 46,XY,t(3;20;13)(p2?2;q12;q14),del(11)(q14) [18]/46,XY[2]//del 13q14, del ATM | Not done |
| CLL-19 | Male | 5 | B | No | 0 | 67 | TPA1 | 47,XY,+12[3]/46,XY[12]//+12 | Sensitive |
| CLL-20 | Female | 5 | A | No | 0 | 73 | CPG | 46,XX[20]//del 13q14† | Sensitive |
| CLL-21 | Male | 5 | A | No | 0 | 72 | TPA2 | 46,XY[20]//del 13q14 | Sensitive |
| CLL-22 | Female | 5 | A | No | 0 | 71 | TPA1 | 47,XX,+12[2]/46,XX[8]//+12 | Sensitive |
| CLL-23 | Male | 5 | B | No | 0 | 54 | CPG | 46,XY[18]//del13q14† | Sensitive |
| CLL-24 | Female | 5 | A | No | 0 | 83 | TPA | 46,XX[20]//del ATM | Sensitive |
| CLL-25 | Female | 4 | A | Yes | 48 | 59 | CPG | 46,XX,del(13)(q14q2?1),add(17)(p12)[cp5]/45-46,idem,-8,-17,+2∼3mar[cp10]/46,XX,del(6) (q1?6q2?4),-9,add(18)(q22),+mar[cp5]// del13q14, del TP53 | Sensitive |
| CLL-26 | Male | 4 | A | Yes | 72 | 53 | CPG | 47,XY,+12[14]/47,idem,der(4)?inv(4)(p?13q?22) t(4;17)(?q31;q22)[3]/46,XY[3]//+12,del13q14§ | Sensitive |
| CLL-27 | Male | 4 | A | No | 0 | 55 | TPA1 | 47,X,-Y,+12,+19[6]/46,XY[14]//+12 | Sensitive |
| CLL-28 | Female | 4 | B | No | 0 | 86 | CPG | 46,XY[20]//del 13q14 | Sensitive |
| CLL-29 | Male | 4 | A | No | 0 | 76 | TPA1 | 46,XY[20]//del 13q14, del TP53 | Sensitive |
| ctrl-1 | Male | 0 | 0 | No | 0 | 26 | CPG | Karyotype not done//no abnormalities | Sensitive |
| ctrl-2 | Male | 0 | 0 | No | 0 | 52 | CPG | Karyotype not done//no abnormalities | Sensitive |
| ctrl-3 | Male | 0 | 0 | No | 0 | 54 | CPG | Karyotype not done//no abnormalities | Sensitive |
Treatments (if any) were received at least 3 months before cell sampling for each experiment. Apoptosis score was established as described.20 Chromosomal aberrations were established by karytoype analysis and FISH using LSI ATM/LSI p53 and LSI D13S319/LSI 13q34/CEP12 probe sets (Abbott), which are complementary to 11q22.3, 17p13.1, 13q14.3, 13q34, and 12p11.1-q11 genome regions, respectively. Data presented take into account the percentage of interphase nuclei with the same chromosomal anomaly (ie, at least 5% of nuclei should contain the same aberration).
+ indicates trisomy; del, deletion; and t, translocation.
Treatments were administered after the study.
Biallelic.
Presence of 2 clones: 1 clone del 13q14 alone and 1 clone del 13q14 and del ATM.
Presence of 2 clones: 1 clone +12 and 1 clone +12 and del 13q14